Reverse transcriptase inhibitors in Aicardi‐Goutières syndrome: Design and regulatory challenges in clinical trials for rare disease

This commentary is on the original article by Crow et al. on pages 750–757 of this issue.

Authors

Institutions

Publication Details

Journal
Developmental Medicine & Child Neurology
Published
2025-01-10
DOI
https://doi.org/10.1111/dmcn.16237
Primary Topic
interferon and immune responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reverse transcriptase inhibitors in Aicardi‐Goutières syndrome: Design and regulatory challenges in clinical trials for rare disease

Russell C. Dale
Developmental Medicine & Child Neurology
interferon and immune responses
article

Reverse transcriptase inhibitors in Aicardi‐Goutières syndrome: Design and regulatory challenges in clinical trials for rare disease

Russell C. Dale
article en

Abstract

This commentary is on the original article by Crow et al. on pages 750–757 of this issue.

Developmental Medicine & Child NeurologyVol. 67(6)
The University of Sydney (AU), Children's Hospital at Westmead (AU)
Openalex Percentile: Top 99%
interferon and immune responses
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Reverse transcriptase inhibitors in Aicardi‐Goutières syndrome: Design and regulatory challenges in clinical trials for rare disease — Russell C. Dale · Developmental Medicine & Child Neurology (2025) | TGRS Research Map | TGRS